Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Supplement Firms Have ‘Continuous Monitoring’ Burden To Show Product Safety

This article was originally published in The Tan Sheet

Executive Summary

Former FDA supplement programs head Bill Frankos says the industry bears the burden for monitoring product safety in the marketplace because FDA does not have the same vested interest it has for drugs and medical devices stemming from pre-market approval of the products.


Related Content

Supplement Adverse Event Reports Sprout In Fertile Field Of Social Media
FDA To Fill Frankos' Shoes As Major Dietary Supplement Initiatives Pend
AER Label Guidance Holds To Requiring Full Addresses For OTCs, Supplements
Supplement GMPs Stress Responsibility, Put Firms In Driver’s Seat For Testing


Related Companies